Print Page  Close Window

SEC Filings

ALLERGAN PLC filed this Form SC TO-T/A on 10/25/2016
Entire Document

Exhibit (a)(1)(L)






Lisa DeFrancesco

(862) 261-7152



Mark Marmur

(862) 261-7558

Allergan Successfully Completes Vitae Tender Offer

– Acquisition Adds Differentiated Development Programs to Strengthen Allergan’s Medical Dermatology Pipeline –

– Vitae’s Contour Drug Discovery Platform and Team Bolsters Allergan’s Discovery Research Capabilities –

DUBLIN, IRELAND – October 25, 2016 – Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced the successful completion of Allergan’s tender offer to purchase all outstanding shares of Vitae Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on innovative development programs for dermatologic conditions. As previously announced, Allergan offered to purchase all outstanding shares of Vitae for $21.00 per share, in cash, for a total transaction value of approximately $639 million.

“The completion of the Vitae acquisition will add highly differentiated development compounds and bolsters our innovative medical dermatology pipeline,” said David Nicholson, Chief R&D Officer, Allergan. “Through its deep expertise in discovering and developing first-in-class compounds in atopic dermatitis, psoriasis and autoimmune diseases, the Vitae team will add important capabilities to Allergan’s Open Science R&D approach.”

The acquisition strengthens Allergan’s dermatology product pipeline, with the addition of VTP-43742, a Phase 2 first-in-class, orally active RORyt (retinoic acid receptor-related orphan receptor gamma) inhibitor for the potential treatment of psoriasis and other autoimmune disorders. The acquisition also adds VTP-38543, a Phase 2a topical LXRß (Liver X Receptor beta) selective agonist for the potential treatment of atopic dermatitis. It is believed that VTP-38543 works by decreasing inflammation in damaged skin tissue and repairing the damaged outer layer of skin.